+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Dermatological Drugs Market Research Reports

From
From
From
Japan CORECTIM Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Japan CORECTIM Market Drug Insight and Market Forecast - 2032

  • Report
  • February 2023
  • 30 Pages
  • Japan
From
TOCTINO Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

TOCTINO Drug Insight and Market Forecast - 2032

  • Report
  • February 2023
  • 30 Pages
  • Global
From
EUCRISA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

EUCRISA Market Drug Insight and Market Forecast - 2032

  • Report
  • February 2023
  • 30 Pages
  • Global
From
STELARA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

STELARA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • Global
From
Nemolizumab Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Nemolizumab Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Difamilast Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Difamilast Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Abrocitinib Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Abrocitinib Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
OPZELURA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

OPZELURA Market Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Chronic Inducible Urticaria Epidemiology Forecast to 2032 - Product Thumbnail Image

Chronic Inducible Urticaria Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032 - Product Thumbnail Image

Chronic Spontaneous Urticaria (CSU) - Epidemiology Forecast - 2032

  • Drug Pipelines
  • January 2022
  • 100 Pages
  • Global
From
Infliximab-Biosimilars Insight, 2022 - Product Thumbnail Image

Infliximab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Adalimumab-Biosimilars Insight, 2022 - Product Thumbnail Image

Adalimumab-Biosimilars Insight, 2022

  • Report
  • January 2022
  • 90 Pages
  • Global
From
Netherton Syndrome - Epidemiology Forecast to 2032 - Product Thumbnail Image

Netherton Syndrome - Epidemiology Forecast to 2032

  • Report
  • January 2022
  • 60 Pages
  • Global
From
From
LY3454738 - Emerging Insight and Market Forecast - 2030 - Product Thumbnail Image

LY3454738 - Emerging Insight and Market Forecast - 2030

  • Report
  • February 2021
  • 35 Pages
  • Global
From
Bullous Pemphigoid - Pipeline Insight, 2025 - Product Thumbnail Image

Bullous Pemphigoid - Pipeline Insight, 2025

  • Clinical Trials
  • April 2025
  • 60 Pages
  • Global
From
Vitiligo - Pipeline Insight, 2025 - Product Thumbnail Image

Vitiligo - Pipeline Insight, 2025

  • Clinical Trials
  • July 2025
  • 80 Pages
  • Global
From
Loading Indicator

The Dermatological Drugs market is a sector of the pharmaceutical industry that focuses on the development and production of drugs used to treat skin conditions. These drugs are used to treat a variety of skin conditions, including acne, eczema, psoriasis, and skin cancer. Dermatological drugs are typically administered topically, although some may be taken orally. The Dermatological Drugs market is highly competitive, with many companies vying for market share. Major players in the market include Johnson & Johnson, GlaxoSmithKline, Pfizer, Merck, and Novartis. These companies are engaged in research and development of new drugs, as well as marketing and distribution of existing products. Additionally, many smaller companies are involved in the production of generic dermatological drugs. Show Less Read more